Pelvic exenteration: experience from a rural cancer center in developing world.

IF 1.6 Q4 ONCOLOGY

International Journal of Surgical Oncology Pub Date : 2015-01-01 Epub Date: 2015-02-08 DOI:10.1155/2015/729658

Sampada B Dessai, Satheesan Balasubramanian, Vijay M Patil, Santam Chakraborty, Atanu Bhattacharjee, Syam Vikram

{"title":"Pelvic exenteration: experience from a rural cancer center in developing world.","authors":"Sampada B Dessai, Satheesan Balasubramanian, Vijay M Patil, Santam Chakraborty, Atanu Bhattacharjee, Syam Vikram","doi":"10.1155/2015/729658","DOIUrl":null,"url":null,"abstract":"Background: Pelvic exenteration (PE) is a morbid procedure. Ours is a rural based cancer center limited trained surgical oncology staff. Hence, this audit was planned to evaluate morbidity and outcomes of all patients undergoing PE at our center.Methods: This is a IRB approved retrospective audit of all patients who underwent PE at our center from January 2010 to August 2013. The toxicity grades were retrospectively assigned according to the CTCAE version 4.02 criteria. Chi-square test was done to identify factors affecting grades 3-5 morbidity. Kaplan Meier survival analysis has been used for estimation of median PFS and OS.Results: 34 patients were identified, with the median age of 52 years (28-73 years). Total, anterior, posterior, and modified posterior exenterations were performed in 4 (11.8%), 5 (14.7%), 14 (41.2%), and 11 (32.4%) patients, respectively. The median time for surgery was 5.5 hours (3-8 hours). The median blood loss was 500 mL (200-4000 mL). CTCAE version 4.02 grades 3-4 toxicity was seen in nine patients (25.7%). The median estimated progression free survival was 31.76 months (25.13-38.40 months). The 2-year overall survival was 97.14%.Conclusion: PE related grades 3-5 morbidity of 25.7% and mortality of 2.9% at our resource limited center are encouraging.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2015 ","pages":"729658"},"PeriodicalIF":1.6000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/729658","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2015/729658","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/2/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pelvic exenteration (PE) is a morbid procedure. Ours is a rural based cancer center limited trained surgical oncology staff. Hence, this audit was planned to evaluate morbidity and outcomes of all patients undergoing PE at our center.

Methods: This is a IRB approved retrospective audit of all patients who underwent PE at our center from January 2010 to August 2013. The toxicity grades were retrospectively assigned according to the CTCAE version 4.02 criteria. Chi-square test was done to identify factors affecting grades 3-5 morbidity. Kaplan Meier survival analysis has been used for estimation of median PFS and OS.

Results: 34 patients were identified, with the median age of 52 years (28-73 years). Total, anterior, posterior, and modified posterior exenterations were performed in 4 (11.8%), 5 (14.7%), 14 (41.2%), and 11 (32.4%) patients, respectively. The median time for surgery was 5.5 hours (3-8 hours). The median blood loss was 500 mL (200-4000 mL). CTCAE version 4.02 grades 3-4 toxicity was seen in nine patients (25.7%). The median estimated progression free survival was 31.76 months (25.13-38.40 months). The 2-year overall survival was 97.14%.

Conclusion: PE related grades 3-5 morbidity of 25.7% and mortality of 2.9% at our resource limited center are encouraging.

Abstract Image

查看原文本刊更多论文

盆腔切除:来自发展中国家农村癌症中心的经验。

背景:盆腔切除(PE)是一种病态的手术。我们是一个农村癌症中心有限的训练有素的外科肿瘤工作人员。因此，本次审核计划评估所有在本中心接受PE治疗的患者的发病率和预后。方法:这是一项IRB批准的回顾性审计，对2010年1月至2013年8月在我中心接受PE治疗的所有患者进行了回顾性审计。根据CTCAE 4.02版标准回顾性分配毒性等级。卡方检验确定影响3-5级发病的因素。Kaplan Meier生存分析用于估计中位PFS和OS。结果:共发现34例患者，中位年龄52岁(28-73岁)。分别对4例(11.8%)、5例(14.7%)、14例(41.2%)和11例(32.4%)患者进行了完全、前路、后路和改良后路拔牙。手术时间中位数为5.5小时(3-8小时)。中位失血量为500 mL (200-4000 mL)。CTCAE 4.02版3-4级毒性9例(25.7%)。中位估计无进展生存期为31.76个月(25.13-38.40个月)。2年总生存率为97.14%。结论:在我们资源有限的中心，3-5级PE相关的发病率为25.7%，死亡率为2.9%，这是令人鼓舞的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Surgical Oncology ONCOLOGY-

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： International Journal of Surgical Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.